Clinical and Scintigraphic Data for Study Population
Parameter | ISM patients (n = 76) | ICM patients (n = 56) | Healthy volunteers (n = 16) |
---|---|---|---|
Sex (M/F) | 62/14 | 43/13 | 9/7 |
Age (y) | 68 ± 12 (range, 28–89)*† | 60 ± 13 (range, 25–87) | 55 ± 16 (15–71) |
NYHA class | 1.8 ± 0.9* | 2.4 ± 1.0 | |
I | 36 | 13 | — |
II | 23 | 14 | — |
III | 15 | 23 | — |
IV | 2 | 6 | — |
Fractional shortening (%) | 25 ± 10*† | 20 ± 12† | 40 ± 6 |
LVDd (mm) | 57 ± 10† | 61 ± 13† | 45 ± 6 |
LVDs (mm) | 44 ± 11*† | 50 ± 15† | 29 ± 4 |
LVEF (%) | 32 ± 11† | 30 ± 11† | 64 ± 9 |
<40% | 55 (72%) | 44 (79%) | — |
Early H/M | 1.95 ± 0.41† | 1.91 ± 0.43† | 2.30 ± 0.17 |
Late H/M | 1.79 ± 0.38† | 1.71 ± 0.41† | 2.38 ± 0.29 |
Mean washout rate (%) | 34 ± 13*† | 42 ± 13† | 20 ± 9 |
No initial uptake | 15 (20%) | 6 (11%) | — |
Follow-up interval (mo) | 54 ± 31 (range, 3–84) | 55 ± 29 (range, 1–84)† | 35 ± 16 |
Prognosis | |||
Survived | 41 (54%) | 33 (59%) | 16 (100%) |
Cardiac death | 28 (37%) | 19 (34%) | 0 (0%) |
Heart failure | 13 | 16 | |
Sudden cardiac death | 9 | 2 | |
Arrhythmia | 1 | 1 | |
Acute myocardial infarction | 5 | 0 | |
Noncardiac death | 7 (9%) | 4 (7%) | 0 (0%) |
AAA rupture | 1 | ||
Sepsis | 2 | ||
BOOP | 1 | ||
Cerebral infarction | 1 | 2 | |
Carcinoma | 1 | 1 | |
Acute respiratory failure | 1 | ||
Unknown | 1 | ||
Concomitant medications | |||
Diuretics | 32 (42%) | 34 (61%) | — |
Digitalis | 23 (30%)* | 36 (64%) | — |
ACE inhibitors | 10 (13%)* | 24 (43%) | — |
β-blockers | 17 (22%) | 13 (23%) | — |
Nitrates | 72 (95%)* | 21 (38%) | — |
Calcium channel blockers | 41 (54%) | 21 (38%) | — |
α-blockers | 4 (5%) | 4 (7%) | — |
↵* P < 0.05 vs. ICM patients.
↵† P < 0.05 vs. healthy volunteers.
NYHA = New York Heart Association; LVDd = left ventricular end-diastolic dimension; LVDs = left ventricular end-systolic dimension; H/M = heart-to-mediastinum ratio; AAA = abdominal aortic aneurysm; BOOP = bronchiolitis obliterans–organizing pneumonia; ACE = angiotensin-converting enzyme.
Values are shown as mean ± SD.